1. Home
  2. NXPL vs ITRM Comparison

NXPL vs ITRM Comparison

Compare NXPL & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXPL
  • ITRM
  • Stock Information
  • Founded
  • NXPL 1997
  • ITRM 2015
  • Country
  • NXPL United States
  • ITRM Ireland
  • Employees
  • NXPL N/A
  • ITRM N/A
  • Industry
  • NXPL Telecommunications Equipment
  • ITRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • NXPL Telecommunications
  • ITRM Health Care
  • Exchange
  • NXPL Nasdaq
  • ITRM Nasdaq
  • Market Cap
  • NXPL 21.9M
  • ITRM 25.7M
  • IPO Year
  • NXPL N/A
  • ITRM 2018
  • Fundamental
  • Price
  • NXPL $1.46
  • ITRM $1.05
  • Analyst Decision
  • NXPL
  • ITRM Strong Buy
  • Analyst Count
  • NXPL 0
  • ITRM 1
  • Target Price
  • NXPL N/A
  • ITRM $5.00
  • AVG Volume (30 Days)
  • NXPL 56.8K
  • ITRM 384.2K
  • Earning Date
  • NXPL 11-12-2024
  • ITRM 08-14-2024
  • Dividend Yield
  • NXPL N/A
  • ITRM N/A
  • EPS Growth
  • NXPL N/A
  • ITRM N/A
  • EPS
  • NXPL N/A
  • ITRM N/A
  • Revenue
  • NXPL $66,404,000.00
  • ITRM N/A
  • Revenue This Year
  • NXPL N/A
  • ITRM N/A
  • Revenue Next Year
  • NXPL N/A
  • ITRM N/A
  • P/E Ratio
  • NXPL N/A
  • ITRM N/A
  • Revenue Growth
  • NXPL 498.52
  • ITRM N/A
  • 52 Week Low
  • NXPL $0.99
  • ITRM $0.62
  • 52 Week High
  • NXPL $2.68
  • ITRM $2.50
  • Technical
  • Relative Strength Index (RSI)
  • NXPL 77.68
  • ITRM 46.10
  • Support Level
  • NXPL $1.15
  • ITRM $0.89
  • Resistance Level
  • NXPL $1.24
  • ITRM $1.18
  • Average True Range (ATR)
  • NXPL 0.07
  • ITRM 0.10
  • MACD
  • NXPL 0.02
  • ITRM -0.00
  • Stochastic Oscillator
  • NXPL 91.09
  • ITRM 60.37

About NXPL NextPlat Corp

NextPlat Corp is a global e-commerce and healthcare company. Its e-commerce venues form an effective global network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operate in two segments: e-Commerce Business and Healthcare Business.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: